Application of Time-to-onset in Drug Safety Surveillance

Abstract

Abstract: Objective Disproportionality analysis is the main method for signal detection and disproportionality analysis is based on the observed and expected values. Recently, time-to-onset (TTO) has been proposed as an effective tool in the adverse drug reactions surveillance. In this study, we aimed to introduce the principle and application of TTO method. Methods We discussed the theory, characteristic, signal detection performance of TTO method through literature review. Results TTO method has played role in signal detection, however, the performance result differed in different studies. Conclusion TTO method could act as an important complementary tool of disproportionality analysis for signal detection.

Key words: time-to-onset, adverse drug reaction, signal detection, disproportionality analysis

CLC Number:

R994.11

YAN Xin-yuan, WANG Yin-cheng, ZHANG Tian-yi, YE Xiao-fei, HOU Yong-fang, WU Gui-zhi, HE Jia. Application of Time-to-onset in Drug Safety Surveillance[J]. Chinese Journal of Pharmacovigilance, 2017, 14(6): 350-352.

References

[1] 叶小飞, 王海南, 陈文,等. 数据挖掘在药物警戒中的应用[J]. 中国药物警戒, 2008, 5(1):36-40.
[2] 任经天, 王胜锋, 侯永芳,等. 常用药品不良反应信号检测方法比较研究[J]. 中国药物警戒, 2011, 8(5):356-359.
[3] 侯永芳, 王玲, 郭秀花,等. 信号检测在药品不良反应监测系统中的应用[J]. 中国药物警戒, 2012, 9(9):539-541.
[4] Maignen F, Hauben M, Tsintis P. Modelling the time to onset of adverse reactions with parametric survival distributions: a potential approach to signal detection and evaluation[J]. Drug Safety, 2010, 33(5):417-434.
[5] Scholl J H, van Puijenbroek E P. The value of time-to-onset in statistical signal detection of adverse drug reactions: a comparison with disproportionality analysis in spontaneous reports from the Netherlands[J]. Pharmacoepidemiology and Drug Safety, 2016, 25(12):1361-1367.
[6] Karimi G, Star K, Norén G N, et al. The Impact of Duration of Treatment on Reported Time-to-Onset in Spontaneous Reporting Systems for Pharmacovigilance[J]. PLoS ONE, 2013, 8(7): e68938.
[7] Aronson J. Anecdotes as evidence[J]. BMJ, 2003; 326(7403): 1346.
[8] Kelly W, Arellano F J, Bergman U, et al. Guidelines for submitting adverse event reports for publication[J]. Drug Safety, 2007,
30(5):367-373.
[9] Van Holle L, Zeinoun Z, Bauchau V, et al. Using time-to-onset for detecting safety signals in spontaneous reports of adverse events following immunization: a proof of concept study[J]. Pharmacoepidemiology and Drug Safety, 2012, 21(6): 603-610.
[10] Van Holle L, Bauchau V. Signal detection on spontaneous reports of adverse events following immunisation: a comparison of the performance of a disproportionality-based algorithm and a time-to-onset-based algorithm[J]. Pharmacoepidemiology and Drug Safety, 2014, 23(2): 178-185.
[11] Van Holle L, Tavares Da Silva F, Bauchau V. Signal detection based on time-to-onset: extending a new method from spontaneous reports to observational studies[J]. Pharmacoepidemiology and Drug Safety, 2014, 23(8): 849-858.
[12] Zhang T, Ye X, Guo X, et al. Signal Detection Based on Time to Onset Algorithm in Spontaneous Reporting System of China[J]. Drug Safety, 2017, 40(4):343-350.
[13] Karimi G, Star K, H?gg S, Norén GN. Time-to-onset in spontaneous reports: the possibility to detect the unexpected[J]. Pharmacoepidemiology and Drug Safety, 2013, 22(5): 556-557.

[1]	JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166.
[2]	LI Yingfen, HAN Lei. Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198.
[3]	XU Weijia, PENG Qi, HUANG Haiyu, ZHANG Leijiao, XIAO Hua, WU Xue. 285 cases of adverse drug reaction related to new antineoplastic drugs [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 199-203.
[4]	GUO Qinghua, PENG Xiaoxiao, ZHU Ping, LIU Xilin, YANG Yinghua, CHEN Zhihai. One case of multiple organ dysfunction syndrome caused by amlodipine overdose [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 204-207.
[5]	FANG Meilin, ZHENG Huimin, WANG Cunze, WANG Ling, RUAN Junshan. One case of generalized myalgia caused by oxaliplatin [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 208-210.
[6]	CHEN Yuyan, ZHANG Mingxia, ZHANG Tao, ZHANG Jin. One case of interstitial pneumonia caused by serplulimab injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 213-215.
[7]	CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili. One case of severe liver injury caused by Tianma Shouwu tablets [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218.
[8]	GUO Longxin, GAO Yunjuan, WU Chengzhao, LONG Minjuan, ZHU Shengkai, SONG Haibo, ZHAO Xu, XIAO Xiaohe. Exploring new risk signals and susceptibility factors of traditional Chinese medicine-induced hepatotoxicity based on big data from adverse reaction monitoring [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 15-19.
[9]	JIANG Wenshuo, YANG Li. Adverse drug reaction among 694 patients in an epilepsy physician-pharmacist joint clinic [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 102-106.
[10]	CHEN Huayan, JIANG Dongbo, GUO Chunlian, YANG Jiaqi, LI Yuxin, CAI Weiming. Safety of nirmatrelvir/ritonavir in the treatment of novel coronavirus infections [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 107-110.
[11]	LIU Saiyue, LYU Xiaoqin, ZHOU Yun. Key points of investigation and report of suspected death of adverse drug reaction [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 971-974.
[12]	LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing. Management of individual adverse drug reaction reports [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977.
[13]	PANG Yu, LIU Bo, LYU Shaoli, WANG Tao, XING Ying, QIN Xingyu, TIAN Yuejie, WU Wenyu. Exploring the significance of collecting patient reports based on international pharmacovigilance experience [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 978-981.
[14]	LIU Wendong, CUI Huanhuan, WANG Xiaohan, SU Xian, WANG Haixue. Status and thinking of Parmacovigilance regulatory system during clinical trials of the pediatric drug in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1002-1006.
[15]	TAI Jun, YU Miao, ZHANG Lin, LEI Yi, LIU Junting, LI Tao, HUANG Guimin, CHENG Yijing, NIE Xiaolu, WANG Qing. Active monitoring of adverse reactions related to haemocoagulase agkistrodon for injection in children [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1011-1016.